These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 32737633

  • 1. Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
    Chuang TY, Li JP, Weng TF, Wu KH, Chao YH.
    Ann Hematol; 2020 Oct; 99(10):2289-2294. PubMed ID: 32737633
    [Abstract] [Full Text] [Related]

  • 2. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH, Chen X, Wu CC, Wu KH, Song TS, Weng TF, Hsieh YW, Peng CT.
    Expert Rev Hematol; 2019 Apr 21; 12(4):265-272. PubMed ID: 30920854
    [Abstract] [Full Text] [Related]

  • 4. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Apr 21; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Apr 21; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 6. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2006 Apr 21; 30(2):219-27. PubMed ID: 16798647
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Apr 21; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 11. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 Apr 10; 33(5):332-8. PubMed ID: 19814679
    [Abstract] [Full Text] [Related]

  • 12. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Apr 10; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 13. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2008 Apr 10; 32(1-2):41-7. PubMed ID: 18274982
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.
    Blood Cells Mol Dis; 2009 Apr 10; 42(3):247-51. PubMed ID: 19233692
    [Abstract] [Full Text] [Related]

  • 16. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.
    Blood Cells Mol Dis; 2010 Aug 15; 45(2):136-9. PubMed ID: 20678715
    [Abstract] [Full Text] [Related]

  • 17. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ.
    Hemoglobin; 2008 Aug 15; 32(1-2):17-28. PubMed ID: 18274979
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial.
    Elalfy MS, Adly A, Awad H, Tarif Salam M, Berdoukas V, Tricta F.
    Am J Hematol; 2018 Feb 15; 93(2):262-268. PubMed ID: 29119631
    [Abstract] [Full Text] [Related]

  • 19. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.
    Ann Hematol; 2008 Jul 15; 87(7):545-50. PubMed ID: 18351337
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.